Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Liabilities (2017 - 2025)

Puma Biotechnology's Total Liabilities history spans 9 years, with the latest figure at $86.0 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 29.08% year-over-year to $86.0 million; the TTM value through Dec 2025 reached $86.0 million, down 29.08%, while the annual FY2025 figure was $86.0 million, 29.08% down from the prior year.
  • Total Liabilities reached $86.0 million in Q4 2025 per PBYI's latest filing, down from $87.6 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $242.2 million in Q1 2021 to a low of $86.0 million in Q4 2025.
  • Average Total Liabilities over 5 years is $166.0 million, with a median of $170.3 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: increased 12.06% in 2021, then tumbled 42.36% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $229.0 million in 2021, then dropped by 12.48% to $200.5 million in 2022, then dropped by 11.66% to $177.1 million in 2023, then crashed by 31.55% to $121.2 million in 2024, then fell by 29.08% to $86.0 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Total Liabilities are $86.0 million (Q4 2025), $87.6 million (Q3 2025), and $90.2 million (Q2 2025).